

Mymetics to advance Preclinical Studies for Virosome-based Covid-19 Vaccine through Innosuisse grant

- *Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform.*
- *Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern University Hospital, in Switzerland, have received a grant from the Swiss Innovation Agency (Innosuisse) to investigate Mymetics' intranasal Covid-19 vaccine candidates in preclinical studies.*
- *This new study will complement Mymetics' other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.*

Epalinges, Switzerland, November 18, 2020 – Mymetics SA, a subsidiary of Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, and Insel Gruppe AG, of which the Inselspital, Bern University Hospital, are part of, today announced that they have been awarded a grant from the Swiss Innovation Agency (Innosuisse). The grant will allow Mymetics in collaboration with the Department of Pneumology at the Inselspital, Bern University Hospital and the Department of Biomedical Research DBMR of Bern University to start a preclinical study which will investigate Mymetics' virosome-based Covid-19 nasal vaccine candidate for safety and tolerance, and its capacity to elicit protective respiratory immunity to block nasal infection and virus spreading to the lungs and brain.

Since April 2020, Mymetics' goal is to develop a safe and highly effective virosome-based Covid-19 vaccine that can be easily administered to all age groups, particularly to immune compromised and elderly populations. The Company is thereby partnering with leading academic institutions to explore and select the best SARS-CoV antigens incorporated into virosome particles, while optimizing the route of administration and thermostability of the vaccine, before moving into human clinical trials.

With the nasal vaccine, Mymetics aims to elicit not only a systemic, but also a protective respiratory immunity with a local memory mucosal immunity, which is often poorly induced by standard intramuscular vaccination.

Prof. Thomas Geiser, the academic research leader of the project and Chairman and Chief Physician of Department of Pneumology at Inselspital, University Hospital Bern, is thankful for the committed research funding from Innosuisse: "We are confronted with an increasing number of Covid-19 patients and are very motivated to collaborate to the development of innovative vaccines. The research at the University Hospital in Bern receives a boost through this funding and recognizes the work of our research teams. The project with Mymetics will



Press Release

be performed at the Department for Biomedical Research (DBMR) of the University of Bern under supervision of Dr. Amiq Gazdar.”

“This grant will allow us to evaluate our intranasal Covid-19 vaccine candidates, for which we aim to induce mucosal neutralizing antibodies and T cells as frontline defense to block SARS-CoV-2 aerosol transmission and nasal infection prior spreading to the lungs, brain and other organs” said Sylvain Fleury, Chief Scientific Officer of Mymetics.

“This Innosuisse funded, University Hospital and University of Bern collaboration is another example of our strategy to access expertise through collaborative approaches to advance towards a safe and highly efficacious Covid-19 virosome based vaccine,” said Ronald Kempers, CEO of Mymetics. “We are grateful to the Innosuisse program and honored to have the opportunity to work with the team of University Hospital and University of Bern and believe their skills and expertise will bring valuable insights in our Covid-19 vaccine development.”

About Mymetics

Mymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has several vaccines in its pipeline, among which are the HIV-1/AIDS, intra-nasal Influenza and malaria, and collaborative projects in the field of allergy immunotherapy and in oncology.

Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on both the mucosal and serum immune response. For further information, please visit www.mymetics.com.

CONTACT:

Mymetics Corporation

Ronald Kempers, CEO
info@mymetics.com
Tel: +41 21 653 4535

Forward looking statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date the statements were made.